Volume 25, Number 7—July 2019
CME ACTIVITY - Synopsis
Prescribing Patterns for Treatment of Mycobacterium avium Complex and M. xenopi Pulmonary Disease in Ontario, Canada, 2001–2013
Table 3
Initial treatment regimen, by prescriber specialty, for 688 patients with Mycobacterium avium complex pulmonary disease, Ontario, Canada, 2001–2013*
Regimen | Specialty, no. (%) patients |
||||
---|---|---|---|---|---|
Respirology, n = 383 (55.7) | ID, n = 69 (10.0) | GIM, n = 51 (7.4) | FP/GP, n = 85 (12.3) | Other/unknown, n = 100 (14.5) | |
Standard triple therapy | 166 (43.3) | 37 (53.6) | 22 (43.1) | 34 (40.0) | 31 (31.0) |
Macrolide monotherapy | 55 (14.4) | 7 (10.1) | <5 (≤9.8) | 14 (16.5) | 15 (15.0) |
Macrolide + rifamycin or fluoroquinolone | 38 (9.9) | ≤5 (≤7.2) | ≤5 (<9.8) | 6 (7.1) | 8 (8.0) |
Other | 124 (32.4) | 20–25 (29.0–36.1) | 20 (39.2) | 31 (36.5) | 46 (46.0) |
*Includes the regimen dispensed for at least the first 60 d of treatment. According to privacy regulations, values representing<6 persons are reported as <5, and data are presented as a range of values for categorical variables where back-calculation is possible. GIM, general internal medicine; FP/GP, family practice/general practice; ID, infectious diseases.